Latest Breaking News On - Clinical actionability - Page 1 : vimarsana.com

Most molecular-targeted cancer therapies show no substantial benefit at approval

Most molecular-targeted cancer therapies show no substantial benefit at approval
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Mindy valcarcelBymatthew shinkleAriadna tibauHarvard medical schoolEuropean society for medical oncologyEuropean societyMedical oncologyClinical actionabilityMolecular targetsClinical benefitClinical benefit scale

Forget lung, breast or prostate cancer: why tumour naming needs to change

The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them. The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them.

United statesFrance generalFabrizio villa gettyGustave roussyEuropean society of medical oncologyNational precision medicine cancer centerAmerican society of clinical oncologyDrug administrationAmerican societyClinical oncologyEuropean societyMedical oncologyClinical benefit scaleClinical actionabilityMedicine cancer center

Nearly half of oncology drugs approved since 1998 are precision therapies

Nearly half of oncology drugs approved since 1998 are precision therapies
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Sarahp suehnholzDebyani chakravartyDrug administrationMemorial sloan kettering cancer centerExpanding landscapeClinical actionabilityCancer discovery

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression on frontline atezolizumab and bevacizumab to targeted therapy or another TKI based on identified genomic alterations.

Comunidad autonoma de catalunaFrance generalCordeliers research centerFrench medicine genomic programInternational liver cancer association conferenceLiver cancer associationWendy limousinSorbonne universitMedicine genomic programClinic liver cancerClinical actionabilityMolecular targetsHepatocellular carcinoma

Should Every Cancer Patient Have Next-Generation Sequencing?

Patients with cancer are increasingly having tumor DNA sequenced to identify disease markers and potential targets, but some investigators question whether every cancer patient can benefit.

United statesDana farber cancer instituteNilay sethiDana farber sethiRamon colomerHarvard medical schoolContra cancer foundationEuropean regional development fundEuropean society for medical oncologyHealth instituteHuman genome projectMedscape medicalUniversidad autHospital universitario la princesaEuropean societyMedical oncology